Show simple item record

dc.contributor.authorHerrington, David M.en_US
dc.contributor.authorSanders, John W.en_US
dc.contributor.authorWierzba, Thomas F.en_US
dc.contributor.authorAlexander-Miller, Marthaen_US
dc.contributor.authorEspeland, Marken_US
dc.contributor.authorBertoni, Alain G.en_US
dc.contributor.authorMathews, Allisonen_US
dc.contributor.authorSeals, Austin L.en_US
dc.contributor.authorMunawar, Iqraen_US
dc.contributor.authorRunyon, Michael S.en_US
dc.contributor.authorMcCurdy, Lewis H.en_US
dc.contributor.authorGibbs, Michael A.en_US
dc.contributor.authorKotloff, Karenen_US
dc.contributor.authorFriedman-Klabanoff, De Annaen_US
dc.contributor.authorWeintraub, Williamen_US
dc.contributor.authorCorrea, Adolfoen_US
dc.contributor.authorUschner, Dianeen_US
dc.contributor.authorEdelstein, SharonEdelstein, Sharon
dc.contributor.authorSantacatterina, Micheleen_US
dc.date.accessioned2021-09-30T13:28:09Z
dc.date.available2021-09-30T13:28:09Z
dc.date.issued2021-08-30
dc.identifier.urihttp://hdl.handle.net/10713/16744
dc.description.abstractBackground: Estimating population prevalence and incidence of prior SARS-CoV-2 infection is essential to formulate public health recommendations concerning the COVID-19 pandemic. However, interpreting estimates based on sero-surveillance requires an understanding of the duration of elevated antibodies following SARS-CoV-2 infection, especially in the large number of people with pauci-symptomatic or asymptomatic disease. Methods: We examined > 30,000 serology assays for SARS-CoV-2 specific IgG and IgM assays acquired longitudinally in 11,468 adults between April and November 2020 in the COVID-19 Community Research Partnership. Results: Among participants with serologic evidence for infection but few or no symptoms or clinical disease, roughly 50% sero-reverted in 30 days of their initial positive test. Sero-reversion occurred more quickly for IgM than IgG and for antibodies targeting nucleocapsid protein compared with spike proteins, but was not associated with age, sex, race/ethnicity, or healthcare worker status. Conclusions: The short duration of antibody response suggests that the true population prevalence of prior SARS-CoV-2 infection may be significantly higher than presumed based on earlier sero-surveillance studies. The impact of the large number of minimally symptomatic COVID-19 cases with only a brief antibody response on population immunity remains to be determined.en_US
dc.description.sponsorshipU.S. Department of Health and Human Servicesen_US
dc.description.urihttps://doi.org/10.1186/s12879-021-06517-6en_US
dc.language.isoen_USen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.ispartofBMC Infectious Diseasesen_US
dc.subjectCOVID-19en_US
dc.subjectHumoral responseen_US
dc.subjectSero-surveillanceen_US
dc.titleDuration of SARS-CoV-2 sero-positivity in a large longitudinal sero-surveillance cohort: the COVID-19 Community Research Partnershipen_US
dc.typeArticleen_US
dc.identifier.doi10.1186/s12879-021-06517-6
dc.identifier.pmid34461847
dc.source.volume21
dc.source.issue1


This item appears in the following Collection(s)

Show simple item record